FDA Update: Mavacamten Approved For Obstructive HCM

The U.S. Food and Drug Administration (FDA) has approved mavacamten (2.5 mg, 5 mg, 10 mg, 15 mg capsules) to improve functional capacity and symptoms in adults with symptomatic NYHA class II-III obstructive hypertrophic cardiomyopathy (HCM).

ACC Joins Coalition in Support of FDA Proposal to Prohibit Menthol Cigarettes, Flavored Cigars

The ACC joined with the Campaign for Tobacco Free Kids and more than 85 other stakeholders in an ad campaign published in the New York Times, Washington Post, and Politico supporting the U.S. Food and Drug Administration's (FDA's) recent proposed product standards prohibiting menthol cigarettes and all flavored cigars.

CMS Releases Proposed 2023 IPPS Rule

The Centers for Medicare and Medicaid Services (CMS) on April 18 released the fiscal year (FY) 2023 proposed Inpatient Prospective Payment (IPPS) Rule.

Don't Be Surprised By 'No Surprises Act'

Implementation of the No Surprises Act, which prohibits out-of-network facilities and providers from balance billing commercially insured patients in certain circumstances and establishes methodology for determining shared costs for out-of-network patients, was the focus of a health policy session during MedAxiom's recent CV Transforum in Atlanta.

The Act, which took effect on Jan. 1, includes a provision requiring protections against balance billing to be publicly disclosed and "good faith" estimates (GFEs) of costs to be provided to self-pay and uninsured patients. According to ACC Advocacy Division Vice President Nick Morse, although the GFE requirement currently pertains only to the uninsured and those who intend to self-pay, the law as written will eventually require GFEs for all patients.

While multiple lawsuits are in play about specific No Surprises Act requirements, implementation of the Act must occur in the meantime. Click here to access American Medical Association resources to help providers navigate the implementation process.